Full Press Release Details
Relyea Elected to the Quintiles Transnational Holdings Inc. Board of
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--December 17,
2013--Quintiles announced today that Mr. Richard Relyea has been elected
to its board of directors. Mr. Relyea was designated by equity investor
3i to fill a vacancy on the Quintiles Transnational Holdings Inc. board
of directors. This comes as the result of Mr. Denis Ribon's pending
departure from 3i and resulting resignation from the Quintiles board.
Pursuant to the Quintiles Transnational Holdings Inc. shareholders
agreement, 3i retains the right to designate a replacement to the board.
Prior to the Quintiles IPO, Mr. Relyea served as 3i's observer to the
Mr. Relyea joined 3i in 2007 as a member of the North American Private
Equity team. He has been involved in 3i's investments in Mold Masters
(Canada), Quintiles (US) and Hilite (Germany).
Prior to joining 3i, Relyea was a principal at Halyard Capital where he
invested in companies in the media, business services and communications
sectors. He also served as an associate at Entrade, where he invested in
technology and internet infrastructure businesses. Relyea began his
career at Security Capital's Preferred Growth Private Equity fund,
investing in real estate operating companies and investment trusts. He
is actively involved in several non-profit organizations and is
president of the New York Private Equity Network. Mr. Relyea received a
B.A. in economics from Williams College.
Quintiles (NYSE: Q) is the world's largest provider of biopharmaceutical
development and commercial outsourcing services with a network of more
than 28,000 employees conducting business in approximately 100
countries. We have helped develop or commercialize all of the top-50
best-selling drugs on the market. Quintiles applies the breadth and
depth of our service offerings along with extensive therapeutic,
scientific and analytics expertise to help our customers navigate an
increasingly complex healthcare environment as they seek to improve
efficiency and effectiveness in the delivery of better healthcare
outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Phil Bridges, Media Relations
1.919.998.1653 (office) +1.919.457.6347 (mobile)
Deonanan, Investor Relations
+1.919.998.2789, (InvestorRelations@quintiles.com)